Novozymes As Stock Performance
| NVZMY Stock | USD 58.60 0.12 0.21% |
The company secures a Beta (Market Risk) of -0.14, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Novozymes are expected to decrease at a much lower rate. During the bear market, Novozymes is likely to outperform the market. At this point, Novozymes AS has a negative expected return of -0.23%. Please make sure to verify Novozymes' kurtosis, as well as the relationship between the rate of daily change and market facilitation index , to decide if Novozymes AS performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Novozymes AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's primary indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 963 M |
Novozymes |
Novozymes Relative Risk vs. Return Landscape
If you would invest 6,826 in Novozymes AS on August 31, 2024 and sell it today you would lose (966.00) from holding Novozymes AS or give up 14.15% of portfolio value over 90 days. Novozymes AS is currently producing negative expected returns and takes up 1.4717% volatility of returns over 90 trading days. Put another way, 13% of traded pink sheets are less volatile than Novozymes, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Novozymes Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novozymes' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Novozymes AS, and traders can use it to determine the average amount a Novozymes' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1571
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NVZMY |
Estimated Market Risk
| 1.47 actual daily | 13 87% of assets are more volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Novozymes is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novozymes by adding Novozymes to a well-diversified portfolio.
Novozymes Fundamentals Growth
Novozymes Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Novozymes, and Novozymes fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novozymes Pink Sheet performance.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 14.47 B | |||
| Shares Outstanding | 276.6 M | |||
| Price To Earning | 34.25 X | |||
| Price To Book | 6.12 X | |||
| Price To Sales | 0.80 X | |||
| Revenue | 17.55 B | |||
| EBITDA | 6.11 B | |||
| Cash And Equivalents | 1.01 B | |||
| Cash Per Share | 3.67 X | |||
| Total Debt | 7.31 B | |||
| Debt To Equity | 0.58 % | |||
| Book Value Per Share | 50.02 X | |||
| Cash Flow From Operations | 4.01 B | |||
| Earnings Per Share | 1.90 X | |||
| Total Asset | 27.98 B | |||
| Retained Earnings | 9.99 B | |||
| Current Asset | 6.08 B | |||
| Current Liabilities | 3.41 B | |||
About Novozymes Performance
Evaluating Novozymes' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Novozymes has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Novozymes has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. Novozymes Unspn is traded on OTC Exchange in the United States.Things to note about Novozymes AS performance evaluation
Checking the ongoing alerts about Novozymes for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Novozymes AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Novozymes AS generated a negative expected return over the last 90 days |
- Analyzing Novozymes' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novozymes' stock is overvalued or undervalued compared to its peers.
- Examining Novozymes' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novozymes' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novozymes' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novozymes' pink sheet. These opinions can provide insight into Novozymes' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Novozymes Pink Sheet Analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.